hpbcd (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
95
Structured Review
MedChemExpress
hpbcd
Hpbcd, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 53 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpbcd/HP-%CE%B2-CD/pmc12436642-65-0-2
Average 95 stars, based on 53 article reviews
Hpbcd, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 53 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpbcd/HP-%CE%B2-CD/pmc12436642-65-0-2
Average 95 stars, based on 53 article reviews
hpbcd - by Bioz Stars,
2026-11
95/100 stars
Images
Related Articles
Control:Article Title: Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade Article Snippet: .. The following drugs were used in this study: 6-diazo-5-oxo-L-norleucine (DON) (Cat#HY-108357), Sirpiglenastat (DRP-104) (Cat#HY-132832), Telaglenastat (CB-839) (Cat#HY-12248), Gefitinib (Cat#HY-50895), U0126 (MEK1 and MEK2 inhibitor, Cat#HY-12031), SP600125 (JNK1/2/3 inhibitor, Cat#HY-12041), L-Glutathione reduced (Cat#HY-D0187), anti-Mouse PD-L1/B7-H1 antibody (10 F.9G2) (Cat#HY- P99145 ), rat lgG2b kappa isotype control (Cat#HY-P990682), Tween 80 (Cat#HY-Y1891), and Article Title: Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade. Article Snippet: .. Drugs The following drugs were used in this study: 6-diazo-5-oxo-L- norleucine (DON) (Cat#HY-108357), Sirpiglenastat (DRP-104) (Cat#HY-132832), Telaglenastat (CB-839) (Cat#HY-12248), Gefitinib (Cat#HY-50895), U0126 (MEK1 and MEK2 inhibitor, AR TIC LE IN PR ES S Cat#HY-12031), SP600125 (JNK1/2/3 inhibitor, Cat#HY-12041), LGlutathione reduced (Cat#HY-D0187), anti-Mouse PD-L1/B7-H1 antibody (10F.9G2) (Cat#HY-P99145), rat lgG2b kappa isotype control (Cat#HY-P990682), Tween 80 (Cat#HY-Y1891), and Article Title: PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma Article Snippet: .. Mice were treated daily with either vehicle control, 3 mg/kg JNJ64619178, or 10 mg/kg JNJ64619178 in a 20% ( Mouse Assay:Article Title: PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma Article Snippet: .. Mice were treated daily with either vehicle control, 3 mg/kg JNJ64619178, or 10 mg/kg JNJ64619178 in a 20% ( Adjuvant:Article Title: Rational design of G i -biased CB1 agonist with reduced side effects. Article Snippet: Article Rational design of Gi-biased CB1 agonist with reduced side effects Recombinant:Article Title: Rational design of G i -biased CB1 agonist with reduced side effects. Article Snippet: Article Rational design of Gi-biased CB1 agonist with reduced side effects Formulation:Article Title: Therapeutic dendrimer Article Snippet: Irinotecan clinical preparation (DBLTM-Irinotecan, Hospira Australia Pty Ltd) was diluted in saline each day of dosing. .. Olaparib solid powder obtained from MedChemExpress was solubilised in DMSO and an oral formulation was prepared at a final concentration of 5 mg/ml in 10% DMSO: 15% ( Concentration Assay:Article Title: Therapeutic dendrimer Article Snippet: Irinotecan clinical preparation (DBLTM-Irinotecan, Hospira Australia Pty Ltd) was diluted in saline each day of dosing. .. Olaparib solid powder obtained from MedChemExpress was solubilised in DMSO and an oral formulation was prepared at a final concentration of 5 mg/ml in 10% DMSO: 15% ( Sterility:Article Title: Therapeutic dendrimer Article Snippet: Irinotecan clinical preparation (DBLTM-Irinotecan, Hospira Australia Pty Ltd) was diluted in saline each day of dosing. .. Olaparib solid powder obtained from MedChemExpress was solubilised in DMSO and an oral formulation was prepared at a final concentration of 5 mg/ml in 10% DMSO: 15% ( |